Ottobock makes follow-on cornerstone investment in NeuroTech company ONWARD Medical

EQS-News: Ottobock SE & Co. KGaA / Key word(s): Investment Ottobock makes follow-on cornerstone investment in NeuroTech company ONWARD Medical 24.10.2025 / 07:44 CET/CEST The issuer is solely responsible for the content of this announcement. Ottobock makes follow-on cornerstone investment in NeuroTech company ONWARD Medical

Duderstadt, 24 October 2025
 

Strengthening Venture Investment in Strategic NeuroTech Partner

Ottobock SE & Co. KGaA (“Ottobock”) has expanded its investment in ONWARD Medical N.V. (“ONWARD Medical”), a European medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities. On Wednesday, 22 October 2025, ONWARD Medical announced the launch of a capital increase, the results of which were announced prior to market opening on Friday, 24 October 2025. ONWARD Medical successfully raised gross proceeds of EUR 50.9 million by way of an accelerated bookbuild offering through a private placement with existing and new institutional investors. Ottobock acted as cornerstone investor in this transaction by investing EUR 10 million and maintains its role as largest shareholder.

The current investment is a follow-on to Ottobock’s initial investment in ONWARD Medical in October 2024, when the MedTech champion invested EUR 22.5 million  and became a cornerstone investor. Since then, ONWARD Medical successfully launched the ARC-EX System in the US market. According to clinical studies, the non-invasive neuromodulation device helped 90% of the participants improve their strength or function in the upper limbs. 30% of the now raised capital should be used to expand sales and operations to support commercialization of the ARC-EX System in the United States, Europe and select other geographies. In addition, 40% should be invested in the company’s investigational implantable ARC-IM System, including but not limited to product development, clinical studies and regulatory activities. The initial focus of ARC-IM being on blood pressure instability in people with spinal cord injury, whilst it has also received FDA Breakthrough Device Designation to restore leg motor function, provide trunk stability, improve bladder control, and reduce spasticity.